About cel-sci - CVM
CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.
CVM At a Glance
CEL-SCI Corp.
8229 Boone Boulevard
Vienna, Virginia 22182
| Phone | 1-703-506-9460 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -26,920,465.00 | |
| Sector | Health Technology | Employees | N/A | |
| Fiscal Year-end | 09 / 2025 | |||
| View SEC Filings |
CVM Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 5.255 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.867 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.181 |
CVM Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
CVM Liquidity
| Current Ratio | 1.312 |
| Quick Ratio | 1.091 |
| Cash Ratio | 1.027 |
CVM Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -93.604 |
| Return on Equity | -206.43 |
| Return on Total Capital | -109.929 |
| Return on Invested Capital | -114.389 |
CVM Capital Structure
| Total Debt to Total Equity | 90.322 |
| Total Debt to Total Capital | 47.458 |
| Total Debt to Total Assets | 43.057 |
| Long-Term Debt to Equity | 72.93 |
| Long-Term Debt to Total Capital | 38.319 |